-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|June 21, 2024

Examining Key Unmet Needs in Multiple Sclerosis

Author(s)Ryan Haumschild, PharmD, MS, MBA, Heidi Crayton, MD , Maria Lopes, MD

Key opinion leaders discuss the most significant unmet needs in the current treatment landscape for multiple sclerosis.

Episodes in this series

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

EP. 1 Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

Video 1 - 3 KOLs are featured in, "Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression"

EP. 2 Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression

Video 2 - 3 KOLs are featured in, "Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis"

EP. 3 Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis

3 KOLs in this program

EP. 4 Examining Key Unmet Needs in Multiple Sclerosis

3 KOLs in this program

EP. 5 Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 6 MS Treatment Guidelines: Expert Insights on Updates and Decision-Making

A panel of 3 experts on multiple sclerosis

EP. 7 Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 8 Examining Challenges with Drug Switching and Step Therapy in MS Treatment

A panel of 3 experts on multiple sclerosis

EP. 9 Typical Payer Coverage Criteria for Multiple Sclerosis Therapies

A panel of 3 experts on multiple sclerosis

EP. 10 BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment

A panel of 3 experts on multiple sclerosis

EP. 11 Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis

A panel of 3 experts on multiple sclerosis

EP. 12 Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies

A panel of 3 experts on multiple sclerosis

EP. 13 Multiple Sclerosis: Looking Toward the Future

What do you view as the biggest unmet needs in the current treatment landscape for MS?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Little boy using in haler. | Image credit: WavebreakmediaMicro_stock.adobe.com

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

BySabrina McCrear

June 24th 2026

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

ByBrooke McCormick

June 23rd 2026

Joseph K. Han, MD

How Upstream Biologics Could Transform CRSwNP Care: Joseph K. Han, MD

BySabrina McCrear,Joseph K. Han, MD

June 23rd 2026

X-ray scan with patient. | Image Credit: DraganaGordic_AdobeStock.jpeg

Familial Pulmonary Fibrosis Linked to Faster Lung Function Decline, UIP Pattern

BySabrina McCrear

June 23rd 2026

Ocrelizumab | Image credit: Semi - stock.adobe.com

Switch to Ocrelizumab Shows Safety in Patients With Relapsing MS

ByJulia Bonavitacola

June 23rd 2026

Trending on AJMC

ATTR-CM Incidence, Prevalence Rose Sharply in the US

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

Mixed Phase 3 Results for IB6-Targeting ADC Raise Questions on Optimal Use in NSCLC

First Generic of Priftin Approved by FDA for Tuberculosis Treatment and Prevention

Natera's Moshkevich Discusses TOMR Approach and the Future of MRD-Guided Care